Evidence map›Paper›PMID 25231984›Full record

ArticleThe Journal of biological chemistry2014

Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo.

Hosadurga Kumar Keerthy, Chakrabhavi Dhananjaya Mohan, Kodappully Sivaraman Siveen, Julian E Fuchs, Shobith Rangappa, Mahalingam S Sundaram, Feng Li, Kesturu S Girish, Gautam Sethi, Basappa and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Identification of Target Genes Related to Sulfasalazine in Triple-Negative Breast Cancer Through Network Pharmacology.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Hosadurga Kumar KeerthyLaboratory of Chemical Biology, Department of Chemistry, Bangalore University, Palace Road, Bangalore 560 001, India.
Chakrabhavi Dhananjaya MohanDepartment of Studies in Chemistry and University of Mysore, Manasagangotri, Mysore 570 006, India.
Kodappully Sivaraman SiveenDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117 597.
Julian E FuchsUnilever Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom.
Shobith RangappaInterdisciplinary Research Group of Infectious Diseases, Singapore-MIT Alliance for Research and Technology Centre (SMART), Singapore 138 602, and.
Mahalingam S SundaramDepartment of Studies in Biochemistry, University of Mysore, Manasagangotri, Mysore 570 006, India.
Feng LiDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117 597.
Kesturu S GirishDepartment of Studies in Biochemistry, University of Mysore, Manasagangotri, Mysore 570 006, India.
Gautam SethiDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117 597,; Cancer Science Institute of Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117 599.
BasappaLaboratory of Chemical Biology, Department of Chemistry, Bangalore University, Palace Road, Bangalore 560 001, India,. Electronic address: salundibasappa@gmail.com.
Andreas BenderUnilever Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom,. Electronic address: ab454@cam.ac.uk.
Kanchugarakoppal Subbegowda RangappaDepartment of Studies in Chemistry and University of Mysore, Manasagangotri, Mysore 570 006, India. Electronic address: rangappaks@yahoo.com.
University of Mysore · INBangalore University · INNational University of Singapore · SGUnilever (United Kingdom) · GBNational University Cancer Institute, Singapore · SGSingapore-MIT Alliance for Research and Technology · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TNF is a pleotropic cytokine known to be involved in the progression of several pro-inflammatory disorders. Many therapeutic agents have been designed to counteract the effect of TNF in rheumatoid arthritis as well as a number of cancers. In the present study we have synthesized and evaluated the anti-cancer activity of novel biscoumarins in vitro and in vivo. Among new compounds, BIHC was found to be the most cytotoxic agent against the HepG2 cell line while exhibiting less toxicity toward normal hepatocytes. Furthermore, BIHC inhibited the proliferation of various hepatocellular carcinoma (HCC) cells in a dose- and time-dependent manner. Subsequently, using in silico target prediction, BIHC was predicted as a TNF blocker. Experimental validation was able to confirm this hypothesis, where BIHC could significantly inhibit the recombinant mouse TNF-α binding to its antibody with an IC50 of 16.5 μM. Furthermore, in silico docking suggested a binding mode of BIHC similar to a ligand known to disrupt the native, trimeric structure of TNF, and also validated with molecular dynamics simulations. Moreover, we have demonstrated the down-regulation of p65 phosphorylation and other NF-κB-regulated gene products upon BIHC treatment, and on the phenotypic level the compound shows inhibition of CXCL12-induced invasion of HepG2 cells. Also, we demonstrate that BIHC inhibits infiltration of macrophages to the peritoneal cavity and suppresses the activity of TNF-α in vivo in mice primed with thioglycollate broth and lipopolysaccharide. We comprehensively validated the TNF-α inhibitory efficacy of BIHC in an inflammatory bowel disease mice model.

Indexed as

AnimalsAnti-Inflammatory AgentsCarcinoma, HepatocellularCoumarinsCytokinesDisease Models, AnimalDrug DesignHepatocytesHep G2 CellsHumansInflammationInflammatory Bowel DiseasesInhibitory Concentration 50Liver NeoplasmsMagnetic Resonance SpectroscopyMiceAnti-Inflammatory AgentsCoumarinsCytokinesNF-kappa BTumor Necrosis Factor-alphaCancer TherapyCell InvasionHepatocellular CarcinomaInflammatory Bowel Disease (IBD)NF-kappa B (NF-KB)Tumor Necrosis Factor (TNF)

Identifiers

PMID25231984
PMCPMC4231667
OpenAlexW1978293354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.